271 related articles for article (PubMed ID: 28892521)
21. Identification of Key Genes and miRNAs in Osteosarcoma Patients with Chemoresistance by Bioinformatics Analysis.
Xie B; Li Y; Zhao R; Xu Y; Wu Y; Wang J; Xia D; Han W; Chen D
Biomed Res Int; 2018; 2018():4761064. PubMed ID: 29850522
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the protein-protein interaction networks of differentially expressed genes in pulmonary embolism.
Wang H; Wang C; Zhang L; Lu Y; Duan Q; Gong Z; Liang A; Song H; Wang L
Mol Med Rep; 2015 Apr; 11(4):2527-33. PubMed ID: 25434468
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profile identifies potential biomarkers for human intervertebral disc degeneration.
Guo W; Zhang B; Li Y; Duan HQ; Sun C; Xu YQ; Feng SQ
Mol Med Rep; 2017 Dec; 16(6):8665-8672. PubMed ID: 29039500
[TBL] [Abstract][Full Text] [Related]
24. Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Kwon K; Jang CS; Noh YH; Kim SY
Cancer Genomics Proteomics; 2015; 12(3):153-66. PubMed ID: 25977174
[TBL] [Abstract][Full Text] [Related]
25. In silico identification of potential key regulatory factors in smoking-induced lung cancer.
El-Aarag SA; Mahmoud A; Hashem MH; Abd Elkader H; Hemeida AE; ElHefnawi M
BMC Med Genomics; 2017 Jun; 10(1):40. PubMed ID: 28592245
[TBL] [Abstract][Full Text] [Related]
26. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
27. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
28. HLA-G Gene Polymorphism in Egyptian Patients with Non-Hodgkin Lymphoma and its Clinical Outcome.
Tawfeek GA; Alhassanin S
Immunol Invest; 2018 Apr; 47(3):315-325. PubMed ID: 29388862
[TBL] [Abstract][Full Text] [Related]
29. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
30. Identification and Interaction Analysis of Molecular Markers in Colorectal Cancer by Integrated Bioinformatics Analysis.
Han B; Feng D; Yu X; Zhang Y; Liu Y; Zhou L
Med Sci Monit; 2018 Aug; 24():6059-6069. PubMed ID: 30168505
[TBL] [Abstract][Full Text] [Related]
31. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract][Full Text] [Related]
32. Differential gene expression analysis and network construction of recurrent cardiovascular events.
Liao J; Chen Z; He Q; Liu Y; Wang J
Mol Med Rep; 2016 Feb; 13(2):1746-64. PubMed ID: 26708382
[TBL] [Abstract][Full Text] [Related]
33. Systems Approach to Pathogenic Mechanism of Type 2 Diabetes and Drug Discovery Design Based on Deep Learning and Drug Design Specifications.
Chang S; Chen JY; Chuang YJ; Chen BS
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375269
[TBL] [Abstract][Full Text] [Related]
34. Delineating the underlying molecular mechanisms and key genes involved in metastasis of colorectal cancer via bioinformatics analysis.
Qi C; Chen Y; Zhou Y; Huang X; Li G; Zeng J; Ruan Z; Xie X; Zhang J
Oncol Rep; 2018 May; 39(5):2297-2305. PubMed ID: 29517105
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer.
Peng C; Ma W; Xia W; Zheng W
Mol Med Rep; 2017 Mar; 15(3):1087-1094. PubMed ID: 28075450
[TBL] [Abstract][Full Text] [Related]
36. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells.
Lewis TS; McCormick RS; Stone IJ; Emmerton K; Mbow B; Miyamoto J; Drachman JG; Grewal IS; Law CL
Leukemia; 2011 Jun; 25(6):1007-16. PubMed ID: 21394099
[TBL] [Abstract][Full Text] [Related]
37. Identification of pivotal genes and pathways for spinal cord injury via bioinformatics analysis.
Zhu Z; Shen Q; Zhu L; Wei X
Mol Med Rep; 2017 Oct; 16(4):3929-3937. PubMed ID: 28731189
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive analysis of candidate genes and pathways in pancreatic cancer.
Liu J; Li J; Li H; Li A; Liu B; Han L
Tumour Biol; 2015 Mar; 36(3):1849-57. PubMed ID: 25409614
[TBL] [Abstract][Full Text] [Related]
39. Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach.
Yang ZZ; Liu W; Zhang F; Li Z; Cheng YY
Acta Pharmacol Sin; 2015 Jun; 36(6):699-707. PubMed ID: 25960133
[TBL] [Abstract][Full Text] [Related]
40. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
